Zimberelimab (GLS-010) is a fully human monoclonal antibody of the IgG4 subclass that targets PD-1 with a high affinity, demonstrated by an EC50 of 210 pM. This antibody effectively inhibits the interaction between PD-1 and its ligands PD-L1 and PD-L2, with IC50 values of 580 pM and 670 pM respectively, in CHO-S cell assays. Zimberelimab has been shown to exhibit potent antitumor activities. It is applicable in the research of various cancers, including cervical cancer, non-small cell lung cancer, and classical Hodgkin’s lymphoma, making it a valuable tool for oncological studies focused on immune checkpoint pathways.
Zimberelimab (GLS-010) is a fully human monoclonal antibody of the IgG4 subclass that targets PD-1 with a high affinity, demonstrated by an EC50 of 210 pM. This antibody effectively inhibits the interaction between PD-1 and its ligands PD-L1 and PD-L2, with IC50 values of 580 pM and 670 pM respectively, in CHO-S cell assays. Zimberelimab has been shown to exhibit potent antitumor activities. It is applicable in the research of various cancers, including cervical cancer, non-small cell lung cancer, and classical Hodgkin’s lymphoma, making it a valuable tool for oncological studies focused on immune checkpoint pathways.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
